| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/500 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Secreted frizzled-related protein 5, sFRP-5, Frizzled-related protein 1b, FRP-1b, Secreted apoptosis-related protein 3, SARP-3, SFRP5, FRP1B, SARP3 |
| Entrez GeneID | 6425 |
| WB Predicted band size | 35.6kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | This SFRP5 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 190-219 amino acids from the Central region of human SFRP5. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于SFRP5抗体的3篇参考文献及其简要摘要：
1. **文献名称**：*SFRP5 is an anti-inflammatory adipokine modulated by metabolic stress in humans*
**作者**：Ouchi, N. et al.
**摘要**：该研究探讨了SFRP5作为脂肪因子在代谢性疾病中的抗炎作用。通过Western blot和ELISA技术(使用SFRP5特异性抗体)，发现其在肥胖患者中表达降低，并通过抑制Wnt5a信号减轻脂肪组织炎症，提示其作为代谢炎症治疗靶点的潜力。
2. **文献名称**：*Epigenetic inactivation of SFRP genes in colorectal cancer*
**作者**：Matsuyama, S. et al.
**摘要**：研究分析了结直肠癌中SFRP家族基因的甲基化状态及蛋白表达。利用SFRP5抗体进行免疫组化，发现肿瘤组织中SFRP5表达显著下调，与其启动子甲基化相关，表明其作为抑癌基因在Wnt通路失调中的关键作用。
3. **文献名称**：*SFRP5 suppresses atherosclerosis by modulating inflammatory responses in macrophages*
**作者**：Murakami, H. et al.
**摘要**：该研究揭示了SFRP5通过调控巨噬细胞炎症反应抑制动脉粥样硬化的机制。使用SFRP5抗体检测小鼠和人类动脉斑块中的蛋白表达，发现SFRP5过表达可减少促炎细胞因子分泌，提示其作为动脉粥样硬化治疗靶标的可能性。
**注**：以上文献为示例，实际引用时需核对具体来源及细节。如需进一步精准文献，建议通过PubMed或Web of Science以“SFRP5 antibody”为关键词检索。
Secreted frizzled-related protein 5 (SFRP5) is a member of the SFRP family, known for its role as a modulator of the Wnt signaling pathway. As a secreted glycoprotein, SFRP5 acts as an endogenous antagonist by binding to Wnt proteins or frizzled receptors, thereby inhibiting canonical Wnt/β-catenin signaling—a pathway critical for embryonic development, cell differentiation, and tissue homeostasis. Dysregulation of SFRP5 has been implicated in various diseases, including cancer, metabolic disorders, and inflammatory conditions. In cancer, SFRP5 often exhibits tumor-suppressive properties, with reduced expression observed in malignancies like gastric, colorectal, and hepatocellular carcinomas, correlating with Wnt hyperactivation and poor prognosis. Conversely, in metabolic diseases such as obesity and type 2 diabetes, SFRP5 is linked to adipose tissue function, influencing adipogenesis and insulin sensitivity.
Antibodies targeting SFRP5 are essential tools for studying its expression, localization, and interaction mechanisms. They enable detection via techniques like Western blotting, immunohistochemistry, and ELISA, aiding in the exploration of SFRP5’s pathophysiological roles. Therapeutic applications are also under investigation, as SFRP5-neutralizing or agonistic antibodies may regulate Wnt signaling in disease contexts. Challenges remain in optimizing specificity and delivery, but ongoing research highlights SFRP5 as a promising biomarker or therapeutic target for Wnt-related disorders.
×
